President and Board of Directors Chair of ISCT from June 2024. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the Committee to better represent the industrial translational objectives and needs of society membership.

CEO of Kiji Therapeutics, Executive Chairman of Akatsuki Therapeutics, member of the Board of StemBond, Swarm Oncology and Blue Cells, consulting through mC4Tx, Professor at the Lisbon University and Board of Directors and Executive Committee member for ARM. 
Previously CEO of Bone Therapeutics (2019-2022) leading the listed company through strategic refocus, several raises and a successful M&A transaction. CEO of Zelluna Immunotherapy (2017-2019), where he established the corporate structure, raised successfully, built the team and launched the strategy for solid tumors allogeneic C>. From 2010-2017 was CMO/COO of TxCell, establishing and leading the professional C> product translation development for autoimmune diseases. Participated on the company IPO and several successful raises. From 2006-2010 was VP of Global Medical Affairs at UCB contributing to the development of the biologics portfolio, product approval and launch. In 2004, joined Nabi Pharmaceuticals as the VP of Medical/Regulatory Affairs for Europe, leading from inception the creation of the vaccine company in Europe. 
After several public sector clinical, academic, and regulatory positions in Portugal and at the European Medicines Agency (EMA), namely as CHMP member, spent six years with BMS (1998-2003). 

Holds an M.D. and Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a Ph.D. in Immunology, University of Birmingham, and a certificate on Health Technologies Economics, Stockholm School of Economics. He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.